Walvax Biotechnology
Walvax Biotechnology Co, Ltd, a biological pharmaceutical company.
Market cap
$2.8b
Enterprise value
$2.5b
Share price
CNY12.67 300142.SZ
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | $72.8m | Post IPO Equity | |
| Total Funding | 000k | ||
No items found
No investors found
| CNY | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 18 % | 47 % | (19 %) | (31 %) | 5 % | 13 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 32 % | 32 % | 34 % | 30 % | 27 % | 27 % | 28 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 12 % | 14 % | 10 % | 5 % | 12 % | 13 % | 14 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 18 % | 18 % | 19 % | 21 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
exited
ACQUISITION by Walvax Biotechnology Jan 2014
ACQUISITION by Walvax Biotechnology Oct 2012